Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2023

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

The following table summarizes stock option activities for the three months ended March 31, 2023:


				Weighted Average
				Remaining
		Weighted Average		Contractual Life (in
	Stock Options	Exercise Price		years)
Outstanding at December 31, 2022	76,112	$	59.09	4.31
Outstanding at March 31, 2023	76,112	$	59.09	4.06
Options vested and exercisable at March 31, 2023	47,570	$	59.09	4.06

Schedule of Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense for the three months ended March 31, 2023 and 2022 (in thousands):


	For the three months ended March 31,
	2023		2022
General and administrative	$	109	$	147
Research and development		126		517
Total stock-based compensation expense	$	235	$	664

Summary of Warrant Activities

A summary of warrant activities for the three months ended March 31, 2023, is presented below:


				Weighted Average
				Remaining
		Weighted Average		Contractual Life (in
	Warrants	Exercise Price		years)
Outstanding as of December 31, 2022	70,195	$	22.80	8.29
Exercised	(93)		—	—
Outstanding as of March 31, 2023	70,102	$	22.80	8.05

Restricted Stock Awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedules of Restricted Stock and Restricted Stock Unit Activity

The following table summarizes restricted stock award activities for the three months ended March 31, 2023:


		Weighted Average
		Grant Date Fair
	Number of Shares	Value
Nonvested at December 31, 2022	34,016	$	22.20
Nonvested at March 31, 2023	34,016	$	22.20

Restricted Stock Units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Schedules of Restricted Stock and Restricted Stock Unit Activity

Certain employees and consultants have been awarded restricted stock units with time-based vesting. The following table summarizes restricted stock units’ activities for the three months ended March 31, 2023:


		Weighted Average
		Grant Date Fair
	Number of Units	Value
Nonvested at December 31, 2022	165,912	$	27.60
Granted	19,398		5.43
Forfeited	(10,699)		35.75
Vested	(14,220)		35.64
Nonvested at March 31, 2023	160,391	$	23.66